Human immunodeficiency virus (HIV)-negative, API2-MALT1 fusion-negative bronchus-associated lymphoid tissue (BALT) lymphoma in a young male

Leuk Lymphoma. 2004 Oct;45(10):2165-8. doi: 10.1080/1042819042000219449.

Abstract

A 22-year-old male presented with multiple bilateral nodular shadows in the lungs by chest radiograph. He had been asymptomatic and showed no significant abnormal findings in laboratory examinations. He underwent a diagnostic partial lobectomy, and was diagnosed as having primary pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma; i.e. bronchus-associated lymphoid tissue (BALT) lymphoma/BALToma. Neither t(11;18)(q21;q21) chromosomal translocation nor API2-MALT1 chimeric transcript was found at diagnosis. Epstein-Barr virus (EBV) was also not detected in lymphoma cells. He had been a nonsmoker, and had also never shown any associated autoimmune disorders, chronic inflammatory lung diseases or human immunodeficiency virus (HIV) infection. However, he had suffered from moderate atopic dermatitis on his arms from childhood. It appears necessary to clarify whether atopy might play a role in the pathogenesis of API2-MALT1(-) BALT lymphoma for HIV(-) young patients who do not exhibit any other antecedent chronic antigenic stimulations.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Murine-Derived
  • Bronchial Neoplasms / diagnosis
  • Bronchial Neoplasms / etiology*
  • Bronchial Neoplasms / therapy
  • Cytogenetic Analysis
  • HIV Seronegativity
  • Humans
  • Immunophenotyping
  • Lymphoma, B-Cell / diagnosis*
  • Lymphoma, B-Cell / etiology*
  • Lymphoma, B-Cell / therapy
  • Lymphoma, Non-Hodgkin / diagnosis
  • Lymphoma, Non-Hodgkin / etiology
  • Lymphoma, Non-Hodgkin / therapy
  • Male
  • Oncogene Proteins, Fusion
  • Polymerase Chain Reaction
  • Remission Induction
  • Rituximab

Substances

  • API2-MALT1 fusion protein, human
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Oncogene Proteins, Fusion
  • Rituximab